Álvarez-Palomo, BelénVeiga, AnnaRaya, AngelCodinach, MargaritaTorrents, SilviaPonce Verdugo, LauraRodriguez-Aierbe, ClaraCuellar, LeopoldoAlenda, RaquelArbona, CristinaHernández-Maraver, DoloresFusté, CristinaQuerol, Sergi2023-05-032023-05-032022-08-12http://hdl.handle.net/10668/20362The increasing number of clinical trials for induced pluripotent stem cell (iPSC)-derived cell therapy products makes the production on clinical grade iPSC more and more relevant and necessary. Cord blood banks are an ideal source of young, HLA-typed and virus screened starting material to produce HLA-homozygous iPSC lines for wide immune-compatibility allogenic cell therapy approaches. The production of such clinical grade iPSC lines (haplolines) involves particular attention to all steps since donor informed consent, cell procurement and a GMP-compliant cell isolation process. Homozygous cord blood units were identified and quality verified before recontacting donors for informed consent. CD34+ cells were purified from the mononuclear fraction isolated in a cell processor, by magnetic microbeads labelling and separation columns. We obtained a median recovery of 20.0% of the collected pre-freezing CD34+, with a final product median viability of 99.1% and median purity of 83.5% of the post-thawed purified CD34+ population. Here we describe our own experience, from unit selection and donor reconsenting, in generating a CD34+ cell product as a starting material to produce HLA-homozygous iPSC following a cost-effective and clinical grade-compliant procedure. These CD34+ cells are the basis for the Spanish bank of haplolines envisioned to serve as a source of cell products for clinical research and therapy.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Cord bloodCord blood banksGMP manufacturingHLA matchingHematopoietic progenitor cellsInduced pluripotent stem cellsAntigens, CD34Blood BanksFetal BloodHomozygoteInduced Pluripotent Stem Cellsresearch article35962457open access10.1186/s13287-022-02961-61757-6512PMC9372949https://stemcellres.biomedcentral.com/counter/pdf/10.1186/s13287-022-02961-6https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372949/pdf